# N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

> **NCT00295919** · PHASE1 · COMPLETED · sponsor: **New Approaches to Neuroblastoma Therapy Consortium** · enrollment: 80 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** fenretinide lipid matrix
- **DRUG:** ketoconazole
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00295919
- **Lead sponsor:** New Approaches to Neuroblastoma Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2014-03
- **Final completion:** 2015-05
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295919, "N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00295919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*